Dr. Sinclair is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
219 Sunset Ave
Ste 116A
Dallas, TX 75208Phone+1 972-807-7370Fax+1 972-807-7381
Summary
- Gary Sinclair, MD is an Infectious Disease specialist based in Dallas, TX with a subspecialty in HIV/AIDS Medicine. He completed his education at Case Western Reserve University/University Hospitals Cleveland Medical Center, including his residency and fellowship roles. Dr. Sinclair has published widely, earning a considerable number of citations, with a focus on HIV-related issues including symptomology, antiretroviral adherence, and treatment methods. He has also conducted clinical trials, notably relating to HIV Acquired Lipodystrophy and Thiazolidinedione treatment. In 2014, he received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, an honor awarded by Epic Systems Corporation.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Infectious Disease, 1997 - 2000- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1994 - 1997
Case Western Reserve University School of MedicineClass of 1994
Certifications & Licensure
ND State Medical License 2013 - 2026
TX State Medical License 2000 - 2026
IN State Medical License 2010 - 2015
NJ State Medical License 2010 - 2015
MI State Medical License 2010 - 2014
OH State Medical License 1996 - 2014
PA State Medical License 2006 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) Start of enrollment: 2009 Oct 01
Publications & Presentations
PubMed
- 3 citationsFactors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the...Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, Ahmed Hnoosh, Antonella Castagna
AIDS Patient Care and Stds. 2023-01-01 - 18 citationsPerspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiv...Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor
Journal of the International AIDS Society. 2022-09-01 - 22 citationsPerspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid II...Cindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor
Journal of the International AIDS Society. 2022-09-01
Press Mentions
Staged Reading of the Yellow Boat Is a Worthwhile Way to Spend World AIDS Day on FridayNovember 30th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
